Drugs / Anti-BCMA-CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07148791 | Sep 2025 → Sep 2027 expected | immune dysregulation, autoimmunity, and autoinflammation, immunoglobulin G4-related sclerosing disease | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-BCMA-CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07148791 ↗ |
| Action | Deplete | “Dual-target CAR-T cells directed against both CD19 and BCMA may achieve more complete depletion of pathogenic B-lineage cells” NCT07148791 ↗ |
| Modality | Cell therapy | “autologous, dual-target chimeric antigen receptor T-cell therapy” NCT07148791 ↗ |
| Route | Intravenous | “CAR-T cells are infused intravenously on Day 0” NCT07148791 ↗ |